Plain-English translation of NCT06031584 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to see if it can safely and effectively treat certain advanced cancers of the digestive system (like stomach or colon) and urinary system (like bladder) that have specific genetic markers called HER2. The study has two parts: first, researchers will figure out the right dose and watch for side effects; then, they'll test whether the medication actually helps shrink tumors in patients with these cancers.
Many cancers of the digestive and urinary systems are hard to treat once they've spread. This medication is designed to target cancer cells with HER2 markers, offering hope for patients who may have limited treatment options.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication in cycles lasting 3 weeks. If the treatment is helping you and you're tolerating it well, you may continue with additional cycles. Throughout the trial, you'll have regular visits for blood tests, heart monitoring, and imaging scans to check how your tumor is responding and to watch for any side effects. Your participation will continue until your cancer stops responding to the treatment, you experience side effects you can't tolerate, or you and your doctor decide to stop for another reason.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
China